Somewhat Positive Press Coverage Somewhat Unlikely to Impact Oncolytics Biotech (ONCY) Stock Price

Media coverage about Oncolytics Biotech (NASDAQ:ONCY) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oncolytics Biotech earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave media coverage about the company an impact score of 48.7015535285678 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of ONCY stock traded down $0.08 during trading hours on Monday, reaching $4.19. The company had a trading volume of 27,900 shares, compared to its average volume of 44,943. Oncolytics Biotech has a twelve month low of $3.64 and a twelve month high of $8.55. The firm has a market cap of $70.58 million, a P/E ratio of -4.93 and a beta of 1.81.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Friday, August 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.25). research analysts expect that Oncolytics Biotech will post -0.95 EPS for the current fiscal year.

A number of research firms have recently issued reports on ONCY. ValuEngine lowered Oncolytics Biotech from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Zacks Investment Research lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Thursday, June 7th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

See Also: Earnings Per Share (EPS)

Insider Buying and Selling by Quarter for Oncolytics Biotech (NASDAQ:ONCY)

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply